CNTY-813 Restores Glycemic Control without Allo-Rejection; IND in 4Q:26

Research evidence excerpt

CNTY-813 Restores Glycemic Control without Allo-Rejection; IND in 4Q:26

rmal glycemic response within 60 minutes, which was durable for at least 8 months. Shares Out (mil) 205.7

In mice with human T and NK cells, unedited islet cells were rejected beginning at Form 10Q as of May 1st + PFWs

3-4 weeks, resulting in the loss of glucose-stimulated insulin release. Likewise, at 11 Market Cap. (mil) US$436.1

weeks after transplant, unedited islet cells showed poor glucose tolerance indicative of Total Assets ($mil) 327

Avg Daily Vol (000) 1,211 rejection. In comparison, CNTY-813 showed no signs of rejection in glucose stimulated

Book Value/Share US$1.29

insulin release or glucose tolerance, demonstrating the success of the Allo-Evasion Price/Book 164%

edits. Century plans to file the IND in 4Q:26 and report initial data in 2H:27. Net Cash Per Share US$1.05

Debt to Total Capital 0.0%

• Scalable Production of CNTY-813 for Clinic. Century has adapted the CNTY-813 Div Yield 0.00%

manufacturing process to use a commercial size bioreactor. Across 3 runs, Century Fiscal Year End Dec

produced a consistently pure cell product with >95% endocrine cells and ~50% insulin-

Price Performance - 1 Year

producing beta islet cells. Other cells types were FEV+ islet cells (26%), alpha cells (6%),

delta cells (1%) and exocrine/delta cells (1%). Ki67 expression (proliferation marker) USD

was low (<1%) and did not increase over time. No cysts or tumors were observed in over 3.5

140 mice. In vitro, CNTY-813 showed similar potency in producing insulin in response to 3

glucose as primary islet cells. These data demonstrate that Century can produce clinical 2.5

supply of CNTY-813 likely further scale manufacturing. 2

1.5

RISKS TO ACHIEVEMENT OF PT & RECOMMENDATION